tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Leukemia D007938 74 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Hematoma D006406 5 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Crohn Disease D003424 12 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Thyroid Diseases D013959 8 associated lipids
Sinusitis D012852 9 associated lipids
Leukocytosis D007964 9 associated lipids
Glomerulonephritis D005921 35 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Hypoglycemia D007003 13 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Pancytopenia D010198 6 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Brain Edema D001929 20 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Gingivitis D005891 3 associated lipids
Periodontal Pocket D010514 9 associated lipids
Brain Infarction D020520 17 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Brain Ischemia D002545 89 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Ischemia D007511 18 associated lipids
Glycosuria D006029 10 associated lipids
Seizures D012640 87 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nerve Degeneration D009410 53 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kuo CJ et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. 1992 Nature pmid:1614535
Moutabarrik A et al. In vitro FK506 kidney tubular cell toxicity. 1992 Transpl. Int. pmid:14621743
Moutabarrik A et al. FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells. 1992 Transpl. Int. pmid:14621744
Stangl MJ et al. The use of FK506 and RS61443 for reversal of small-bowel rejection. 1992 Transpl. Int. pmid:14621800
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Wijnen RM et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. 1992 Transpl. Int. pmid:14621844
Lee C et al. FK-506 binding protein from Tolypocladium inflatum: resistance of FKBP/FK-506 complex against proteolysis. 1992 Biochem. Biophys. Res. Commun. pmid:1371677
Jiang H et al. Control of humoral and cellular immunity-mediated accelerated heart allograft rejection in sensitized rats by low dose FK 506 and splenectomy. 1992 Transpl. Int. pmid:14621859
Edkins RD et al. Comparison of cyclosporine and FK506 effects on glutathione levels in rat cochlea, brain, liver and kidney. 1992 Biochem. Pharmacol. pmid:1371687
Kobayashi N et al. Abdominal organ cluster transplantation in pigs and FK506. 1992 Transpl. Int. pmid:14621861
Galat A et al. A rapamycin-selective 25-kDa immunophilin. 1992 Biochemistry pmid:1371698
Hanawa H et al. An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. 1992 Clin. Immunol. Immunopathol. pmid:1371730
Hiraoka Y et al. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. 1992 J. Pharmacol. Exp. Ther. pmid:1372051
Chen TS et al. Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 J. Antibiot. pmid:1372307
Lepre CA et al. Solution structure of FK506 bound to FKBP-12. 1992 FEBS Lett. pmid:1375171
Ruff VA et al. FKBP-12 is not an inhibitor of protein kinase C. 1992 Immunol. Invest. pmid:1375189
Kawaguchi S [Effects of FK506 on aminonucleoside-induced nephrotic rats]. 1992 Nihon Jinzo Gakkai Shi pmid:1375300
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Chen TS et al. Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by an unidentified Actinomycete ATCC 53828 [corrected]. 1992 J. Antibiot. pmid:1375593
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. 1992 Transplant. Proc. pmid:1376532
Demetris AJ et al. Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. 1992 Lancet pmid:1376851
Ichihashi T et al. Haemolytic uraemic syndrome during FK506 therapy. 1992 Lancet pmid:1376852
O'Keefe SJ et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. 1992 Nature pmid:1377361
Souza ER et al. Acute effects of FK 506 on glomerular hemodynamics. 1992 Transplant. Proc. pmid:1281585
Hanke JH et al. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. 1992 Lymphokine Cytokine Res. pmid:1281674
Logan TM et al. Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments. 1992 FEBS Lett. pmid:1281793
Bergstrand H et al. Modulation of neutrophil superoxide generation by inhibitors of protein kinase C, calmodulin, diacylglycerol and myosin light chain kinases, and peptidyl prolyl cis-trans isomerase. 1992 J. Pharmacol. Exp. Ther. pmid:1281879
DiLella AG et al. Chromosomal band assignments of the genes encoding human FKBP12 and FKBP13. 1992 Biochem. Biophys. Res. Commun. pmid:1281998
Sawada M et al. Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide. 1992 Biochem. Biophys. Res. Commun. pmid:1282000
Minoda M et al. Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. 1992 Microbiol. Immunol. pmid:1282197
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Kobayashi N et al. Abdominal organ cluster transplantation in pigs receiving FK 506. 1992 Transplant. Proc. pmid:1379754
Yoshimura R et al. A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. 1992 Transplant. Proc. pmid:1379755
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Dumont FJ et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. 1992 J. Exp. Med. pmid:1380976
Norris AA et al. Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs. 1992 Clin. Exp. Immunol. pmid:1381297
Karpas A et al. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1381509
Yatscoff RW and Shaw LM Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. 1992 Ther Drug Monit pmid:1381530
Arceci RJ et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. 1992 Blood pmid:1381629
Pahl A and Keller U FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. 1992 J. Bacteriol. pmid:1381710
Hultsch T et al. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. 1992 Mol. Biol. Cell pmid:1384815
Petros AM et al. Identification of solvent-exposed regions of an FK-506 analog, ascomycin, bound to FKBP using a paramagnetic probe. 1992 J. Biomol. NMR pmid:1384850
Liu J et al. The effects of FK-506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6. 1992 Int. Arch. Allergy Immunol. pmid:1384862
Mochizuki M et al. Preclinical and clinical study of FK506 in uveitis. 1992 Curr. Eye Res. pmid:1385045
Chung J et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. 1992 Cell pmid:1377606